skip to main content
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Management of venous thromboembolism in patients with cancer

López‐Núñez, J. J. ; Trujillo‐Santos, J. ; Monreal, M.

Journal of thrombosis and haemostasis, 2018-12, Vol.16 (12), p.2391-2396 [Periódico revisado por pares]

England: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
  • Título:
    Management of venous thromboembolism in patients with cancer
  • Autor: López‐Núñez, J. J. ; Trujillo‐Santos, J. ; Monreal, M.
  • Assuntos: anticoagulant therapy ; Anticoagulants ; bleeding ; Cancer ; Cancer therapies ; death ; Health risk assessment ; Patients ; recurrences ; Thromboembolism ; Thrombosis ; venous thromboembolism
  • É parte de: Journal of thrombosis and haemostasis, 2018-12, Vol.16 (12), p.2391-2396
  • Descrição: Summary Current guidelines for anticoagulant therapy do not so far suggest any form of differentiated approach to cancer patients with venous thromboembolism (VTE). This review article provides an overview of the published literature in cancer patients with VTE, mostly using data from the RIETE registry. Our findings provide some insights into what factors may be used to guide physicians in adapting recommended anticoagulant regimens to the individual patient, as oncologists are increasingly doing with cancer treatments. For instance, patients presenting with deep vein thrombosis (DVT) alone might benefit from curtailing treatment intensity as anticoagulant therapy progresses. The site of cancer also needs to be considered. In patients with incidental PE or splanchnic vein thrombosis, we should be more cautious before prescribing anticoagulant therapy. The optimal duration of anticoagulant therapy is unknown.
  • Editor: England: Wiley Subscription Services, Inc
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.